Tag: PHARMAKONZERN
-
Eli Lilly’s Legislative Gains: Investigating Influences and Implications in Germany
Internal documents reveal that the German government amended laws to accommodate Eli Lilly’s requests for confidential pricing in exchange for significant investments in a new manufacturing facility. This situation raises concerns about transparency and the potential impact on healthcare costs and policies. According to internal documents from the German Ministry of Health, the federal government…